Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Merck & Co. claims glucagon antagonists, cytokine inhibitors

Sep. 2, 1998

Banyu presents urea derivatives with NPY receptor-antagonist activity

Sep. 2, 1998

L-168721: potent, nonpeptide GH secretagogue

Sep. 2, 1998

P&U to market Glyset in U.S., Canada and several other countries

Sep. 2, 1998

Hemosol blood substitute to enter phase II clinical trials in U.S. for CABG

Sep. 2, 1998

Novartis continues to study DPP IV inhibitors; new lead reported at ACS meeting

Sep. 1, 1998

Novo Nordisk describes the first nonpeptide competitive glucagon antagonist

Sep. 1, 1998

Androsorb to enter second part of hormone replacement therapy trial

Sep. 1, 1998

New ACAT inhibitors synthesized at Sumitomo

Aug. 31, 1998

Columbia Laboratories develops hormone replacement tablet for men

Aug. 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...